Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 281 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 50 or 100 mg Clear all
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 4 Interventional Results available

Multi-dose Acetaminophen for Patients Undergoing General Anesthesia

NCT02832687
View directory record Official record
Conditions
Recovery Following Cholecystectomy
Interventions
Acetaminophen, normal saline
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Newark, New Jersey • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 14, 2026, 4:54 AM EDT
Recruiting Phase 4 Interventional

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

NCT07542756
View directory record Official record
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

NCT03701555
View directory record Official record
Conditions
Digestive System Disease
Interventions
PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg
Other · Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

NCT02499120
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
palbociclib, Cetuximab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

NCT01523990
View directory record Official record
Conditions
Healthy, Hepatitis C, Chronic
Interventions
TG-2349, placebo
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Pharmacological Agents for Chronic Spinal Cord Injury (SCI)

NCT05708274
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
CPH + hand training, CD-LD + hand training, ATX + hand training, Placebo + hand training
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342
View directory record Official record
Conditions
Schizophrenia
Interventions
PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Rogers, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00718718
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

NCT02877134
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

NCT00993382
View directory record Official record
Conditions
Arrhythmia Prophylaxis, Ventricular Arrhythmia
Interventions
Celivarone, Amiodarone, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Huntsville, Alabama • Mobile, Alabama • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

SMART Use of Medication for the Treatment of Adolescent Severe Obesity

NCT04007393
View directory record Official record
Conditions
Adolescent Obesity
Interventions
Lifestyle Modification Therapy (LSMT), Phentermine Pill, Topiramate Pill, Placebo
Behavioral · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003
View directory record Official record
Conditions
Major Depression
Interventions
Lamotrigine, Ketamine, Riluzole
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

NCT05071612
View directory record Official record
Conditions
OSA - Obstructive Sleep Apnea
Interventions
AD109, AD504, Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

NCT00455429
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 14, 2026, 4:54 AM EDT